Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,255 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Water Clear all
Completed Early Phase 1 Interventional Results available

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

NCT00734994
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Interventions
Hyperthermia System, Mitomycin C
Device · Drug
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MRSA Colonization and Control in the Dallas County Jail

NCT00785200
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Skin Diseases, Infectious, Soft Tissue Infections
Interventions
Chlorhexidine, Water
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4,194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Oct 17, 2026, 4:49 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

NCT03107871
View directory record Official record
Conditions
Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
Interventions
Valganciclovir, Simple Syrup
Drug
Lead sponsor
Albert Park
Other
Eligibility
1 Month to 12 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Results available

Skin and Soft Tissue Infection (SSTI) Study

NCT02600871
View directory record Official record
Conditions
Skin Diseases, Infectious, Soft Tissue Infections
Interventions
Provodine, Incision and Drainage
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 17, 2026, 4:49 PM EDT
Terminated Phase 2 Interventional Results available

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

NCT01436045
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

NCT01954745
View directory record Official record
Conditions
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Not applicable Interventional

Effect of Smartphone Application on Reducing Localized Inflammation in Periodontal Maintenance Patients

NCT04546295
View directory record Official record
Conditions
Periodontal Inflammation
Interventions
Brushlink application, Water-flosser, Interproximal brush
Other
Lead sponsor
University of Nebraska
Other
Eligibility
40 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Results available

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

NCT01707667
View directory record Official record
Conditions
Chronic Constipation
Interventions
prucalopride, PEG 3350
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

NCT04966507
View directory record Official record
Conditions
Gonorrhea
Interventions
Listerine Antiseptic Mouthwash Product, Biotene Mouthwash
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 4:49 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 17, 2026, 4:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Body Water Content in Cyanotic Congenital Heart Disease

NCT00000107
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
17 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 17, 2026, 4:49 PM EDT
Terminated Phase 3 Interventional Results available

Binge Eating Liraglutide Intervention

NCT03279731
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
Drug
Lead sponsor
Kelly Allison
Other
Eligibility
21 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 17, 2026, 4:49 PM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

NCT01509339
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Vancomycin
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 17, 2026, 4:49 PM EDT
Terminated Not applicable Interventional

Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study

NCT03938441
View directory record Official record
Conditions
Diabetes Type 2, Pre-diabetes
Interventions
Intermittent Fasting
Other
Lead sponsor
gino gaddini
Federal
Eligibility
18 Years to 69 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 17, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

NCT06390956
View directory record Official record
Conditions
Marginal Zone Lymphoma
Interventions
Pirtobrutinib, Rituximab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 17, 2026, 4:49 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

NCT04534322
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
Melphalan Flufenamide, Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
Springdale, Arkansas • Coeur d'Alene, Idaho • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 1 Interventional

Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain

NCT04193631
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Cannabidiol (CBD)
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chadds Ford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 17, 2026, 4:49 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Trial of Kuvan in Lesch-Nyhan Disease

NCT00935753
View directory record Official record
Conditions
Behavioral Manifestations of Lesch-Nyhan Disease
Interventions
sapropterin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Donepezil on Smoking

NCT01250977
View directory record Official record
Conditions
Smoking
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 17, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

NCT00393029
View directory record Official record
Conditions
Anti-p53 TCR-Gene
Interventions
anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 17, 2026, 4:49 PM EDT
Not listed Not applicable Interventional

Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)

NCT05413395
View directory record Official record
Conditions
Eczema
Interventions
topical colloidal oatmeal formulation with a modified plant oil, topical colloidal oatmeal formulation
Other
Lead sponsor
GlycosBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 17, 2026, 4:49 PM EDT